‘As the market has turned’: Enveda secures $68M to move revised pipeline into the clinic in 2023

Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt.

Founded by an early employee at AI startup Recursion Pharmaceuticals, Enveda has adjusted its priorities...

Click to view original post